Academic Journal
From substance-induced psychosis to schizophrenia: Predictors of treatment response and transition to chronic psychotic illness-A systematic review.
| Τίτλος: | From substance-induced psychosis to schizophrenia: Predictors of treatment response and transition to chronic psychotic illness-A systematic review. |
|---|---|
| Συγγραφείς: | Ricci V; University of Turin, Italy; San Luigi Gonzaga Hospital Regione Gonzole 10, 10043, Italy; Regione Gonzole, 10, 10043, Turin, Italy. Electronic address: valerio.ricci@unito.it., Chiappini S; Psychiatry Department, Unicamillus International University of Medical Science, Rome, Italy., Martinotti G; Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio Chieti-Pescara, 66100, Chieti, Italy., Maina G; University of Turin, Italy; San Luigi Gonzaga Hospital Regione Gonzole 10, 10043, Italy; Regione Gonzole, 10, 10043, Turin, Italy; Department of Neurosciences 'Rita Levi Montalcini', University of Turin, Italy. |
| Πηγή: | Schizophrenia research [Schizophr Res] 2026 Sep; Vol. 295, pp. 292-316. Date of Electronic Publication: 2026 Mar 24. |
| Τύπος έκδοσης: | Journal Article; Systematic Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Science Publisher B. V Country of Publication: Netherlands NLM ID: 8804207 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2509 (Electronic) Linking ISSN: 09209964 NLM ISO Abbreviation: Schizophr Res Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Amsterdam : Elsevier Science Publisher B. V., c1988- |
| Ιατρικοί όροι (MeSH): | Psychoses, Substance-Induced*/therapy , Psychoses, Substance-Induced*/diagnosis , Schizophrenia*/therapy , Schizophrenia*/diagnosis , Psychotic Disorders* , Disease Progression*, Humans ; Chronic Disease ; Prognosis |
| Περίληψη: | Background: Substance-induced psychotic disorders (SIPDs) present significant clinical challenges with variable outcomes. While some patients achieve complete remission following substance cessation, others develop persistent symptoms requiring extended intervention. Understanding treatment response predictors is critical for optimizing clinical management and prognostic accuracy. Methods: Following PRISMA guidelines, we systematically searched PubMed, Scopus, Web of Science, PsycINFO, and Embase (inception to October 2024) for studies examining treatment response predictors in SIPDs. We assessed certainty of evidence using modified GRADE criteria for prognostic factor research. Results: Twenty-seven studies representing approximately 33,500 SIPD patients with follow-up ranging from 1 month to 15.5 years met inclusion criteria. Moderate-certainty evidence indicates that acute symptom onset within 24-48 h of substance use predicts favorable treatment response, while prominent negative symptoms predict slower remission and higher transition to chronic psychotic disorders. Moderate-certainty evidence supports that poor premorbid functioning and bimodal response patterns (rapid remission within 30 days vs poor outcomes thereafter) distinguish treatment responders from non-responders. Low-certainty evidence suggests early age of substance use onset, family history of psychotic disorders, abstinence achievement, and premorbid cognitive capacity influence outcomes. Very low-certainty evidence from small neuroimaging studies suggests preserved brain structure and normal dopaminergic function may predict sustained remission. Cannabis-induced and methamphetamine-induced psychosis warrant particular caution given higher persistence rates and psychiatric comorbidity. Conclusions: Treatment response in SIPDs is determined by multiple interacting factors. Moderate-certainty predictors (temporal onset, negative symptoms, premorbid functioning) provide the strongest basis for clinical decision-making, while lower-certainty findings require validation before widespread implementation. (Copyright © 2026 Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors have contributed to the manuscript and approved the final version for submission. The authors confirm that this manuscript has not been published elsewhere and is not under consideration by another journal. The authors have no conflicts of interest to disclose. |
| Contributed Indexing: | Keywords: Antipsychotic medication; Cannabis psychosis; Prognosis; Remission predictors; Stimulant psychosis; Substance-induced psychosis; Treatment response |
| Entry Date(s): | Date Created: 20260325 Date Completed: 20260810 Latest Revision: 20260818 |
| Update Code: | 20260819 |
| DOI: | 10.1016/j.schres.2026.02.022 |
| PMID: | 41881716 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1573-2509 |
|---|---|
| DOI: | 10.1016/j.schres.2026.02.022 |